-
1
-
-
77952112006
-
Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
-
Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-1703.
-
(2010)
Lancet
, vol.375
, pp. 1695-1703
-
-
Lees, K.R.1
Bluhmki, E.2
Von Kummer, R.3
-
3
-
-
79952073474
-
Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: Patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes
-
Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011;123:750 -758.
-
(2011)
Circulation
, vol.123
, pp. 750-758
-
-
Fonarow, G.C.1
Smith, E.E.2
Saver, J.L.3
-
4
-
-
77955665657
-
Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: An updated analysis from SITS-ISTR
-
Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-874.
-
(2010)
Lancet Neurol
, vol.9
, pp. 866-874
-
-
Ahmed, N.1
Wahlgren, N.2
Grond, M.3
-
5
-
-
84867879470
-
Reducing in-hospital delay to 20 minutes in stroke thrombolysis
-
Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 2012;79: 306 -313.
-
(2012)
Neurology
, vol.79
, pp. 306-313
-
-
Meretoja, A.1
Strbian, D.2
Mustanoja, S.3
Tatlisumak, T.4
Lindsberg, P.J.5
Kaste, M.6
-
6
-
-
79959981013
-
Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: A doubling of treatment rates over the course of 5 years
-
Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42:1952-1955.
-
(2011)
Stroke
, vol.42
, pp. 1952-1955
-
-
Adeoye, O.1
Hornung, R.2
Khatri, P.3
Kleindorfer, D.4
-
7
-
-
80053298469
-
Improving doorto-needle times in acute ischemic stroke: The design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative
-
Fonarow GC, Smith EE, Saver JL, et al. Improving doorto-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: stroke initiative. Stroke 2011; 42:2983-2989.
-
(2011)
Stroke
, vol.42
, pp. 2983-2989
-
-
Fonarow, G.C.1
Smith, E.E.2
Saver, J.L.3
-
8
-
-
8644230974
-
Ultrasoundenhanced systemic thrombolysis for acute ischemic stroke
-
Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasoundenhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351:2170 -2178.
-
(2004)
N Engl J Med
, vol.351
, pp. 2170-2178
-
-
Alexandrov, A.V.1
Molina, C.A.2
Grotta, J.C.3
-
9
-
-
66849141260
-
After European Cooperative Acute Stroke Study 3: Mission accomplished?
-
von Kummer R. After European Cooperative Acute Stroke Study 3: mission accomplished? Stroke 2009;40:2268-2270.
-
(2009)
Stroke
, vol.40
, pp. 2268-2270
-
-
Von Kummer, R.1
|